Works by Patnaik, Amita

Results: 42
    1
    2

    Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y
    By:
    • Chia-Chi Lin;
    • Beeram, Muralidhar;
    • Rowinsky, Eric K.;
    • Takimoto, Chris H.;
    • Ng, Chee M.;
    • Geyer Jr., Charles E.;
    • Denis, Louis J.;
    • De Bono, Johann S.;
    • Hao, Desiree;
    • Tolcher, Anthony W.;
    • Rha, Sun-Young;
    • Jolivet, Jacques;
    • Patnaik, Amita
    Publication type:
    Article
    3

    Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
    By:
    • Chia-Chi Lin;
    • Calvo, Emiliano;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Sarantopoulos, John;
    • Mita, Alain C.;
    • Preston, Glenn G.;
    • Mita, Monica M.;
    • Rodon, Jordi;
    • Mays, Theresa;
    • I.-Tien Yeh;
    • O'Rourke, Pat;
    • Takimoto, Chris H.;
    • Dancey, Janet E.;
    • Chen, Helen;
    • Tolcher, Anthony W.
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Lack of Meaningful Effect of Ridaforolimus on the Pharmacokinetics of Midazolam in Cancer Patients: Model Prediction and Clinical Confirmation.

    Published in:
    Journal of Clinical Pharmacology, 2014, v. 54, n. 11, p. 1256, doi. 10.1002/jcph.331
    By:
    • Stroh, Mark;
    • Talaty, Jennifer;
    • Sandhu, Punam;
    • McCrea, Jacqueline;
    • Patnaik, Amita;
    • Tolcher, Anthony;
    • Palcza, John;
    • Orford, Keith;
    • Breidinger, Sheila;
    • Narasimhan, Narayana;
    • Panebianco, Deborah;
    • Lush, Richard;
    • Papadopoulos, Kyriakos P.;
    • Wagner, John A.;
    • Trucksis, Michele;
    • Agrawal, Nancy
    Publication type:
    Article
    10
    11
    12
    13
    14

    Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

    Published in:
    2017
    By:
    • Infante, Jeffrey;
    • Patnaik, Amita;
    • Verschraegen, Claire;
    • Olszanski, Anthony;
    • Shaheen, Montaser;
    • Burris, Howard;
    • Tolcher, Anthony;
    • Papadopoulos, Kyriakos;
    • Beeram, Muralidhar;
    • Hynes, Scott;
    • Leohr, Jennifer;
    • Lin, Aimee;
    • Li, Lily;
    • McGlothlin, Anna;
    • Farrington, Daphne;
    • Westin, Eric;
    • Cohen, Roger;
    • Infante, Jeffrey R;
    • Verschraegen, Claire F;
    • Olszanski, Anthony J
    Publication type:
    journal article
    15
    16
    17
    18

    A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 5, p. 951, doi. 10.1007/s00280-014-2426-8
    By:
    • Patnaik, Amita;
    • LoRusso, Patricia;
    • Messersmith, Wells;
    • Papadopoulos, Kyriakos;
    • Gore, Lia;
    • Beeram, Muralidhar;
    • Ramakrishnan, Vanitha;
    • Kim, Amy;
    • Beyer, Joseph;
    • Mason Shih, L.;
    • Darbonne, Walter;
    • Xin, Yan;
    • Yu, Ron;
    • Xiang, Hong;
    • Brachmann, Rainer;
    • Weekes, Colin
    Publication type:
    Article
    19
    20
    21
    22

    A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 1041, doi. 10.1007/s00280-013-2099-8
    By:
    • Sandhu, Shahneen;
    • Papadopoulos, Kyri;
    • Fong, Peter;
    • Patnaik, Amita;
    • Messiou, Christina;
    • Olmos, David;
    • Wang, George;
    • Tromp, Brenda;
    • Puchalski, Thomas;
    • Balkwill, Frances;
    • Berns, Birge;
    • Seetharam, Shobha;
    • Bono, Johann;
    • Tolcher, Anthony
    Publication type:
    Article
    23
    24

    A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 4, p. 567, doi. 10.1007/s00280-012-1942-7
    By:
    • Lush, Richard;
    • Patnaik, Amita;
    • Sullivan, Daniel;
    • Papadopoulos, Kyriakos;
    • Trucksis, Michele;
    • McCrea, Jacqueline;
    • Cerchio, Kristine;
    • Li, Xiaodong;
    • Stroh, Mark;
    • Selverian, Diana;
    • Orford, Keith;
    • Ebbinghaus, Scot;
    • Agrawal, Nancy;
    • Iwamoto, Marian;
    • Wagner, John;
    • Tolcher, Anthony
    Publication type:
    Article
    25
    26
    27
    28
    29
    30

    Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

    Published in:
    Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1
    By:
    • Rhoda Molife, L.;
    • Li Yan;
    • Vitfell-Rasmussen, Joanna;
    • Zernhelt, Adriane M.;
    • Sullivan, Daniel M.;
    • Cassier, Philippe A.;
    • Eric Chen;
    • Biondo, Andrea;
    • Tetteh, Ernestina;
    • Siu, Lillian L.;
    • Patnaik, Amita;
    • Papadopoulos, Kyriakos P.;
    • De Bono, Johann S.;
    • Tolcher, Anthony W.;
    • Minton, Susan
    Publication type:
    Article
    31
    32
    33
    34

    A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

    Published in:
    Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325
    By:
    • Tolcher, Anthony;
    • Flaherty, Keith;
    • Shapiro, Geoffrey I.;
    • Berlin, Jordan;
    • Witzig, Thomas;
    • Habermann, Thomas;
    • Bullock, Andrea;
    • Rock, Edwin;
    • Elekes, Agnes;
    • Lin, Chester;
    • Kostic, Dusan;
    • Ohi, Naoto;
    • Rasco, Drew;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Smith, Lon;
    • Cote, Gregory M.
    Publication type:
    Article
    35
    36

    First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7
    By:
    • Berlin, Jordan;
    • Tolcher, Anthony W.;
    • Ding, Cliff;
    • Whisenant, Jennifer G.;
    • Horak, Ivan D.;
    • Wood, Debra L.;
    • Nadler, Paul I.;
    • Hansen, Ulla Holm;
    • Lantto, Johan;
    • Skartved, Niels Jørgen Ø.;
    • Pedersen, Mikkel W.;
    • Patnaik, Amita
    Publication type:
    Article
    37
    38
    39
    40
    41
    42